It is critical to future proof an organization to meet changing customer demands, says CDMO Aton Bio. In January, Shanghai Henlius Biotech launched contract development manufacturing organization (CDMO) Aton Biotech to initially serve the China market but with global ambitions. The CDMO is utilizing capacity and capabilities from its parent firm. Min Park, chief business officer at Aton, told BioProcess Insider at BIO “the facility has 48,000 L [of] bioreactor capacity” and the CDMO is responsible for manufacturing five commercial…